Recently, the Office of the Leading Group for the National High-Tech Enterprise Recognition Management announced the fourth batch of 4,400 high-tech enterprises designated by Beijing’s certifying bodies in 2023. AccuMedical Beijing Ltd. was included in the list and designated as a National High-Tech Enterprise.
Science and technology are the primary productive forces and the primary source of competitive advantage. The National High-Tech Enterprise Recognition policy aims to guide enterprises in adjusting their industrial structure, promoting independent innovation, and fostering continuous innovation. This policy encourages enterprises to enhance their technological innovation capabilities. By achieving the “National High-Tech Enterprise” qualification, AccuMedical demonstrates its strong capabilities in independent research and development, the transformation of scientific and technological achievements, and its research and development management systems, all of which have been recognized and supported by the state. This recognition further highlights the company's advanced position in areas such as intellectual property, technological innovation, and the transformation of scientific achievements.
AccuMedical has always focused on addressing unmet clinical needs in the field of cerebrovascular diseases, continuously innovating in products and techniques. The company has research and development centers in both Beijing, China and California, USA. By leveraging these dual R&D centers, AccuMedical actively invests in cutting-edge technologies in neurointerventional medical devices, establishing an international, interdisciplinary, and experienced R&D team and building a comprehensive R&D system. The company has overcome key challenges and mastered core design, R&D, and manufacturing technologies for neurointerventional medical devices, independently developing several core technologies. As of December 2023, AccuMedical has filed more than 88 patents, 43 of which have been granted. Many of its technologies are firsts in the world.
AccuMedical adheres to the concept of technological self-reliance and independence, upholding its corporate value of “treating others as one would oneself.” The company is committed to providing innovative solutions for global patients with cerebrovascular diseases and doctors, aiming for "true innovation and true usage" in the localization of medical devices. The company remains focused on filling the unmet clinical needs in the field of cerebrovascular diseases, improving the accessibility of innovative medical technologies, and leading the innovative development of neurointerventional treatments.